title: Immunogenicity of Haemophilus influenzae oligosaccharide-protein and polysaccharide-protein conjugate vaccination of children at 4, 6, and 14 months of age.
abstract: At 4 and 6 months of age, 118 infants were vaccinated with either one of two Haemophilus influenzae type b capsular polysaccharide-protein conjugate vaccines: 72 infants received the polysaccharide coupled to diphtheria toxoid (PRP-D group), and 46 infants received polysaccharide-derived oligosaccharides coupled to CRM197 protein, a nontoxic mutant form of diphtheria toxin (HbOC group). A third dose of the same vaccine was given to 40 children in the PRP-D group and 25 children in the HbOC group at 14 months of age. Antibodies to the H influenzae type b capsular polysaccharide were measured by Farr-type radioimmunoassay in serum samples taken before each vaccination and 1 month after the second and the third doses. Adverse reactions monitored by a questionnaire were mild. After two vaccine doses, the geometric mean concentration of antibodies to H influenzae type b polysaccharide increased from 0.07 micrograms/mL in the prevaccination samples to 0.63 micrograms/mL in the PRP-D group and to 4.32 micrograms/mL in the HbOC group. In the following 7 months, the geometric mean concentrations declined to 0.38 and 1.12 micrograms/mL, respectively. The booster dose given at 14 months elicited a strong antibody response in both groups (to geometric mean concentrations of 29.7 and 58.3 micrograms/mL, respectively). Both vaccines appear to be capable of immunologic priming by immunization in infancy.
authors.affiliation: National Public Health Institute, Helsinki, Finland.
authors.forename: H
authors.initials: H
authors.lastname: Käyhty
authors.forename: H
authors.initials: H
authors.lastname: Peltola
authors.forename: J
authors.initials: J
authors.lastname: Eskola
authors.forename: P R
authors.initials: PR
authors.lastname: Rönnberg
authors.forename: E
authors.initials: E
authors.lastname: Kela
authors.forename: V
authors.initials: V
authors.lastname: Karanko
authors.forename: P H
authors.initials: PH
authors.lastname: Mäkelä
mesh_terms: D000367:Age Factors; D000914:Antibodies, Viral / Q000096:biosynthesis*; D000917:Antibody Formation; D001428:Bacterial Vaccines / Q000009:adverse effects / Q000276:immunology*; D004168:Diphtheria Toxoid / Q000009:adverse effects / Q000276:immunology*; D018073:Haemophilus Vaccines; D006801:Humans; D007115:Immunization Schedule; D007223:Infant
chemical_list: D000914:Antibodies, Viral; D001428:Bacterial Vaccines; D004168:Diphtheria Toxoid; D018073:Haemophilus Vaccines; C052180:Haemophilus influenzae type b-polysaccharide vaccine-diphtheria toxoid conjugate